Merger Of The Greats: Stifel Provides Green Thumb, Trulieve Merger Rumour Thoughts

In a note sent to investors this morning, Andrew Partheniou of Stifel GMP headlined, “A thought piece on GTII-TRUL merger chatter.” As there has been growing speculation of a Trulieve Cannabis (CSE: TRUL) and Green Thumb Industries (CSE: GTII) merger. Partheniou walks us through the details.

In the scenario, Partheniou believes Green Thumb would buy Trulieve at a 30-40% premium.

Partheniou states that the pro-forma enterprise value would be between $5.3 to $6.3 billion and could go as high as $7.3 billion on re-rating. Combined revenues are estimated to be roughly $5.4 billion yearly and would be double the sales of the next peer down the line, but with better profitability and a stronger scaling advantage which could warrant a higher multiple by the street.

Partheniou then goes on to say that this merger would remove “growth obstacles for both companies.” He then states that the free cash flow generated by Trulieve’s Florida operations could be put towards Green Thumb’s attractive markets such as IL, PA, NJ, and OH and possibly NY if it approves recreational. This deal would also benefit Trulieve as they get a “diversified platform, removing a long-standing share overhang.”

In terms of what would happen to management, Partheniou says that in one scenario, as Green Thumb has not appointed a COO, Trulieve’s CEO Kim Rivers could be appointed and work with Green Thumbs current CEO. The second scenario would be for Mr. Kolver to step down and transition to become the executive chairman of the board, while Kim Rivers becomes the CEO. While the third scenario would be to only integrate the back office and keep the business running separately.

Partheniou sees the main obstacle to the rumoured merger as being the will of management with the US cannabis market hitting ~$16 billion in 2020. The US market could have multiple cannabis giants that can grow rapidly and not take on M&A risk as Canada did, and even if a merger were announced, it wouldn’t be risk-free, with Partheniou outlining a transition risk.

Partheniou states that there is also some asset overlap between the companies, specifically in MA, which would mean the company would have to divest their assets in MA completely. Although MA is an attractive market, the M&A market has been depressed for some time as companies have been rethinking their growth strategies and not expanding into new markets as a result.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Video Articles

The Gold Trade Is Shifting From Margins to Growth | Geordie Mark – Blue Jay Gold

CopAur Minerals – This PEA Has A Mine Life of What?!

Ontario’s Fast Track to Silver Production Is Starting to Matter | Frank Basa – Nord Precious Metals

Recommended

Antimony Resources Trenching at Bald Hill Averages 19.5% Antimony, Peaks at 44.2%

Amid CBS Shuffle, Is Joe Rogan Replacing Anderson Cooper On 60 Minutes?

Related News

GAGE Cannabis: PI Financial Reiterates Their Street High Target, Lowers 2021 Estimates

On August 24, Gage Growth Corp. (CSE: GAGE) announced their second quarter financial results. The...

Saturday, August 28, 2021, 11:13:00 AM

Apple: Analysts Anticipate Q3 Revenues Of $73.3 Billion

Apple (NASDAQ: AAPL) will be reporting their fiscal third quarter on July 27th after market...

Sunday, July 25, 2021, 03:14:00 PM

Xebec Adsorption: Canaccord Smacks Price Target Down From $5.00 To $2.25

Last week, Xebec Adsorption (TSX: XBC) announced its fourth quarter and full-year financial results. The...

Sunday, March 20, 2022, 03:13:00 PM

Shopify CEO Tobi Lütke Wants Financial Analysts To Be Held Accountable

Tobias Lütke, founder and CEO of Shopify, Inc. (TSX: SHOP), took to Twitter to ponder...

Tuesday, May 10, 2022, 04:28:00 PM

CareRx: Canaccord Raises Price Target To $6.50 Following Financing

Earlier this week, CareRx Corp (TSX: CRRX) closed their C$21.2 million bought deal. Notably, $6.25...

Friday, February 5, 2021, 11:45:00 AM